Altimmune (MEX:ALT1) Cyclically Adjusted Revenue per Share: MXN0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ALT1 Altimmune Inc MEX:ALT1
28 GF Score
Price MXN48.50
! 2 Warning Signs
View Full Analysis

What is Altimmune Cyclically Adjusted Revenue per Share?

Altimmune MEX:ALT1 28 Cyclically Adjusted Revenue per Share is MXN0.00 as of Mar. 2026. GuruFocus rates MEX:ALT1 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Altimmune's adjusted revenue per share for the three months ended in Mar. 2026 was MXN0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Altimmune was -25.70% per year. The lowest was -38.10% per year. And the median was -29.60% per year.

As of today (2026-08-02), Altimmune's current stock price is MXN48.50. Altimmune's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN0.00. Altimmune's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Altimmune was 2.86. The lowest was 0.01. And the median was 0.18.


Altimmune  (MEX:ALT1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Altimmune was 2.86. The lowest was 0.01. And the median was 0.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Altimmune Cyclically Adjusted Revenue per Share Related Terms


Altimmune Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Altimmune's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune Cyclically Adjusted Revenue per Share Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 994.25 348.16 336.43 0.00 0.00

Altimmune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:ALT1 vs VSTM, PRME, RLMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Altimmune's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's Cyclically Adjusted PS Ratio falls into.


MEX:ALT1
28GF Score
Altimmune Inc MEX:ALT1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altimmune Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Altimmune's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Altimmune Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 12.704 241.018 17.405
201609 0.422 241.428 0.577
201612 21.691 241.432 29.667
201703 0.407 243.801 0.551
201706 0.221 244.955 0.298
201709 0.946 246.819 1.266
201712 370.039 246.524 495.658
201803 72.214 249.554 95.554
201806 49.679 251.989 65.101
201809 37.297 252.439 48.788
201812 5.600 251.233 7.360
201903 6.042 254.202 7.849
201906 2.379 256.143 3.067
201909 0.861 256.759 1.107
201912 0.722 256.974 0.928
202003 3.434 258.115 4.393
202006 0.932 257.797 1.194
202009 1.963 260.280 2.490
202012 1.265 260.474 1.604
202103 0.440 264.877 0.549
202106 0.066 271.696 0.080
202109 0.079 274.310 0.095
202112 1.578 278.802 1.869
202203 0.014 287.504 0.016
202206 0.003 296.311 0.003
202209 0.001 296.808 0.001
202212 -0.043 296.797 -0.048
202303 0.008 301.836 0.009
202306 0.002 305.109 0.002
202309 0.118 307.789 0.127
202312 0.011 306.746 0.012
202403 0.001 312.332 0.001
202406 0.001 314.175 0.001
202409 0.001 315.301 0.001
202412 0.001 315.605 0.001
202503 0.001 319.799 0.001
202506 0.001 322.561 0.001
202509 0.001 324.800 0.001
202512 0.004 324.054 0.004
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN0.00 mean?
Altimmune (MEX:ALT1) has a Cyclically Adjusted Revenue per Share of MXN0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Altimmune and its competitors.
Is Altimmune's Cyclically Adjusted Revenue per Share too high?
Altimmune's current Cyclically Adjusted Revenue per Share is MXN0.00. Overall, Altimmune has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Altimmune's Cyclically Adjusted Revenue per Share compare to VSTM and PRME?
Altimmune's Cyclically Adjusted Revenue per Share of MXN0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Altimmune and its competitors. Altimmune's current Cyclically Adjusted Revenue per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altimmune stock overvalued right now?
Altimmune (MEX:ALT1) has a current Cyclically Adjusted Revenue per Share of MXN0.00. The current Cyclically Adjusted Revenue per Share is MXN0.00. Altimmune's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Altimmune (MEX:ALT1), the current Cyclically Adjusted Revenue per Share is MXN0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altimmune Business Description

Other Exchanges ALT:USA0A4C:UK3G0:Germany
Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
28GF Score

Get the complete analysis for MEX:ALT1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.50
Price